Paclitaxel (EP/IP/USP)
Alchem International with 75 years of experience in the phytochemical space has been diligently providing plant derived ingredients, active pharmaceutical ingredients and bulk drugs to all international significant geographies.
The success of the company's operations lie in its proprietary manufacturing processes, intensive research, willingness to combat new challenges, mesh with evolving technologies ,focussed expansion and credible response to international validations and inspections.
The production sites are US FDA approved and WHO and EU GMP certified. The company has filed ASMF/DMFs in over 20 countries worldwide. Value additions through bio-technology, semi-synthesis and foot prints in the formulation space have happened in planned progression. Alchem's interest in skin care is a logical part of this dimensional growth.
Sheer Quality drives Alchem’s operations
Through perfect blend of science and nature, dedicated research, selection of finest botanical herbal extracts and focused technology, Alchem has successfully extracted the potent active molecules in the plant and offers it for pharmaceutical use to help various companies spread wellness.
Paclitaxel
"For pharmaceutical use, Alchem offers Paclitaxel with all its inherent benefits"
Paclitaxel is obtained via a semi-synthetic process from Taxus baccata and belongs to the group of cancer-fighting medications known as anti-neoplastics. It is classified as a "plant alkaloid," a "taxane", an "antimicrotubule agent" and an "immunosuppressant".
Paclitaxel is one of several cytoskeletal drugs that target tubulin. It binds to tubulin, the protein component of microtubules, simultaneously promoting their assembly and disassembly to form stable, nonfunctional microtubules. Stabilization of microtubules blocks cells in the M phase of the cell cycle, inhibiting cell division and causing cell death. Paclitaxel acts as a radiosensitizing agent by blocking cells in the G2phase. Paclitaxel treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division.
Paclitaxel is used to treat patients with lung cancer, ovarian cancer, breast cancer, head and neck cancer, prostate, melanoma, esophageal, and other types of solid tumor cancers. It works by slowing or stopping the growth of cancer cells in your body. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi's sarcoma. It is also used as an antiproliferative agent for the prevention of restenosis (recurrent narrowing) of coronary stents. Locally delivered to the wall of the coronary artery, a paclitaxel coating limits the growth of neointima (scar tissue) within stents. Aside from its direct clinical use, paclitaxel is used extensively in biological and biomedical research as a microtubule stabilizer.
The product addresses broad spectrum physiological concerns and has the band width and capabilities to meet expectations. Regular use should exhibit demonstrable results to inhibit various health related issues.
